Oxycodone for neuropathic pain in adults

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 7, 2016, Pages

  Gaskell, Helen ^a   Derry, Sheena ^a   Stannard, Cathy ^b   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE; PLACEBO; DELAYED RELEASE FORMULATION; NARCOTIC ANALGESIC AGENT;

ADD ON THERAPY; ADULT; ANALGESIA; CONTROLLED CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DATA EXTRACTION; DIABETIC NEUROPATHY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; INFORMATION PROCESSING; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SOMNOLENCE; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); AGED; CHEMICALLY INDUCED; CONSTIPATION; DELAYED RELEASE FORMULATION; DIABETIC NEUROPATHIES; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; NEURALGIA, POSTHERPETIC; THERAPEUTIC USE;

ADULT; AGED; ANALGESICS, OPIOID; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DIABETIC NEUROPATHIES; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEURALGIA, POSTHERPETIC; OXYCODONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84979687840     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010692.pub3     Document Type: Review

References (123)

1. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60(6):927-34. [DOI: 10.1212/01.WNL.0000057720.36503.2C]
2. Jensen MP, Friedman M, Bonzo D, Richards P. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105(1-2):71-8. [DOI: 10.1016/S0304-3959(03)00160-X]
3. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain 2008;12(6):804-13. [DOI: 10.1016/j.ejpain.2007.12.010]
4. Mundipharma Research GmbH & Co KG (Responsible Party). An exploratory, randomised, double-blind, single-dummy, placebo controlled, parallel group study to demonstrate the analgesic efficacy of oxycodone/naloxone prolonged release tablets in addition to pregabalin compared to pregabalin alone in opioid-naïve subjects treated with pregabalin suffering from moderate to severe pain due to diabetic polyneuropathy, 2012. www.clinicaltrials.gov/ct2/show/NCT00944697 (accessed 4 February 2016). [CTG: NCT00944697]
5. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50(6):1837-41. [DOI: 10.1212/WNL.50.6.1837]
6. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105(1-2):71-8. [DOI: 10.1016/S0304-3959(03)00160-X]
7. Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opinion on Pharmacotherapy 2010;11(11):1787-804. [DOI: 10.1517/14656566.2010.497720]
8. EUCTR2004-003752-19-HU A randomized, double-blind, placebo- and active-controlled, double-dummy, parallel group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in subjects with moderate to severe, chronic nonmalignant pain - OXN in moderate to severe, chronic nonmalignant pain, 2016. www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2004-003752-19-HU (accessed 28 January 2016). [EUCTR2004-003752-19-HU]
9. EUCTR2005-003510-15-DE A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of 60 - 80 mg/day as oxycodone/naloxone prolonged release (OXN) compared to subjects taking oxycodone prolonged release tablets alone, 2016. www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2005-003510-15-DE (accessed 28 January 2016). [EUCTR2005-003510-15-DE]
10. Gatti A, Sabato AF, Occhioni R, Colini Baldeschi G, Reale C. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. European Neurology 2009;61(3):129-37. [DOI: 10.1159/000186502]
11. Green J, Dain B, Munera C, Gimbel J, Potts J, Berger B. A randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of oxycodone/ naloxone extended-release tablets (OXN) in opioid-experienced subjects with chronic low back pain. Journal of Pain 2014;15(4 Suppl 1):S89.
12. Purdue Pharma LP (Responsible Party). A randomized, double-blind, placebo-controlled, multicenter trial with an enriched study design to assess the efficacy and safety of oxycodone/naloxone controlled-release tablets (oxn) compared to placebo in opioid-experienced subjects with moderate to severe pain due to chronic low back pain who require around-the-clock opioid therapy, 2015. www.clinicaltrials.gov/ct2/show/NCT01358526 (accessed 28 January 2016). [CliniclaTrials.gov: NCT01358526;]
13. Hale ME, Fleischmann R, Salzman R, Wild J, Iwan T, Swanton RE, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clinical Journal of Pain 1999;15(3):179-83. [PUBMED: 10524470]
14. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. Journal of Pain 2005;6(1):21-8. [DOI: 10.1016/j.jpain.2004.09.005]
15. He B-Y. Analgesic effect of oxycodone-acetaminophen tablet in treatment of backleg pain [sic]. Chinese Journal of New Drugs 2009;18(7):623-5. [EMBASE: 2009220662]
16. ISRCTN76170309 A randomised, crossover study of study drug 038 and controlled-release oxycodone HCl tablets in patients with chronic non-cancer pain, 2016. www.isrctn.com/ISRCTN76170309 (accessed 28 January 2016). [DOI: 10.1186/ISRCTN76170309]
17. Kopecky E, O'Connor M, Varanasi R, Saim S, Fleming A. Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study. Journal of Pain 2015;16(4):S87. [DOI: 10.1016/j.jpain.2015.01.364]
18. Kopecky EA (Study director). A phase 3, multi-center, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of oxycodone DETERx™ versus placebo in opioid-experienced and opioid-naive subjects with moderate-to-severe chronic low back pain, 2016. www.clinicaltrials.gov/ct2/show/NCT01685684 (accessed 28 January 2016). [CTG: NCT01685684]
19. Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Advances in Therapy 2010;27(6):381-99. [DOI: 10.1007/s12325-010-0036-3]
20. Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opinion on Pharmacotherapy 2009;10(4):531-43. [DOI: 10.1517/14656560902796798]
21. NCT00412100 A randomised [sic], double-blind, double-dummy, parallel-group multicentre study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of 60-80 mg/day as oxycodone/naloxone prolonged release compared to subjects taking oxycodone prolonged release tablets alone, 2016. www.clinicaltrials.gov/ct2/show/NCT00412100 (accessed 28 January 2016). [ClinicalTrials.gov : NCT00412100;]
22. Dworkin RH (Principal investigator). Trial of analgesia with lidocaine or extended-release oxycodone for neuropathic pain treatment in multiple sclerosis (TALENT-MS), 2016. www.clinicaltrials.gov/ct2/show/NCT00414453 (accessed 28 January 2016). [CTG: NCT00414453]
23. NCT0049176 A study to evaluate the effectiveness and safety of tapentadol (CG5503) extended release (ER) in patients with moderate to severe chronic low back pain, 2016. www.clinicaltrials.gov/ct2/show/NCT0049176 (accessed 28 January 2016). [CTG: NCT0049176]
24. NCT00784810 A double-blind, double-dummy, parallel group, randomised study to compare the efficacy & tolerability of oxycodone/naloxone prolonged release (OXN PR) & codeine/paracetamol in the treatment of moderate to severe chronic low back pain or pain due to osteoarthritis, 2016. www.clinicaltrials.gov/ct2/show/NCT00784810 (accessed 28 January 2016). [CTG: NCT00784810]
25. NCT01014559 Study of efficacy of OXN PR, compared to Oxy PR, for reduction of intensity of opioid-induced constipation symptoms in pts treated for cancer or non-cancer pain: a randomised, double-blind, controlled, multicentre study, 2016. www.clinicaltrials.gov/ct2/show/NCT01014559 (accessed 28 January 2016). [CTG: NCT01014559]
26. NCT01427270 A randomized, double-blind, double-dummy, placebo-controlled, active-controlled, parallel-group, multicenter trial of oxycodone/naloxone controlled-release tablets (OXN) to assess the analgesic efficacy (compared to placebo) and the management of opioid-induced constipation (compared to oxycodone controlled-release tablets (OXY)) in opioid-experienced subjects with uncontrolled moderate to severe chronic low back pain and a history of opioid-induced constipation who require around-the-clock opioid therapy, 2016. www.clinicaltrials.gov/ct2/show/NCT01427270 (accessed 28 January 2016). [CTG: NCT01427270]
27. NCT01427283 A randomized, double-blind, double-dummy, placebo-controlled, active-controlled, parallel-group, multicenter trial of oxycodone/naloxone controlled-release tablets (OXN) to assess the analgesic efficacy (compared to placebo) and the management of opioid-induced constipation (compared to oxycodone controlled-release tablets (OXY)) in opioid-experienced subjects with moderate to severe chronic low back pain and a history of opioid-induced constipation who require around-the-clock opioid therapy, 2016. www.clinicaltrials.gov/ct2/show/NCT01427283 (accessed 28 January 2016). [CTG: NCT01427283]
28. NCT01438567 A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation and non-inferiority in analgesic efficacy in subjects with non-malignant or malignant pain that require around-the-clock opioid therapy taking 50/25 - 80/40 mg twice daily as oxycodone/naloxone prolonged release (OXN PR) tablets compared to subjects taking 50 - 80 mg twice daily oxycodone prolonged release (OxyPR) tablets alone, 2016. www.clinicaltrials.gov/ct2/show/NCT01438567 (accessed 28 January 2016). [CTG: NCT01438567]
29. NCT01439100 A randomised placebo controlled study of OXN PR for severe Parkinson's disease associated pain, 2016. www.clinicaltrials.gov/ct2/show/NCT01439100 (accessed 28 January 2016). [CTG: NCT01439100]
30. NCT01502644 Opioid treatment for chronic low back pain and the impact of mood symptoms, 2016. www.clinicaltrials.gov/ct2/show/NCT01502644 (accessed 28 January 2016). [CTG: NCT01502644]
31. NCT02321397 Randomised, double-blind, double-dummy, cross-over multicenter study to demonstrate equivalence in analgesic efficacy & bowel function taking oxycodone equivalents of 120 & 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) BID compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy, 2016. www.clinicaltrials.gov/ct2/show/NCT02321397 (accessed 28 January 2016). [CTG: NCT02321397]
32. Simpson K (Principal investigator). A randomised, double-blind, parallel-group, multicentre study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of >20 mg/day and <50 mg/day as oxycodone/naloxone prolonged release compared to subjects taking oxycodone prolonged release tablets alone, 2016. www.clinicaltrials.gov/ct2/show/NCT00412152 (accessed 28 January 2016). [CTG: NCT00412152]
33. Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Current Medical Research and Opinion 2008;24(12):3503-12. [DOI: 10.1185/03007990802584454]
34. NCT00313014 A multicenter, randomized, double-blind, active comparator study to determine the efficacy and safety of BTDS 20 or oxycodone immediate-release versus BTDS 5 in subjects with moderate to severe low back pain, 2016. www.clinicaltrials.gov/ct2/show/NCT00313014 (accessed 28 January 2016). [CTG: NCT00313014]
35. Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. Journal of Pain 2011;12(11):1163-73. [DOI: 10.1016/j.jpain.2011.06.003]
36. NCT01971632 A randomised, double blind, placebo and active controlled, double dummy, parallel group study to determine the safety and efficacy of oxycodone/naloxone prolonged release tablets in subjects with moderate to severe, chronic nonmalignant pain, 2016. www.clinicaltrials.gov/ct2/show/NCT01971632 (accessed 28 January 2016). [CTG: NCT01971632]
37. Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. Journal of Pain 2008;9(12):1144-54. [DOI: 10.1016/j.jpain.2008.06.014]
38. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. Journal of Pain 2006;7(12):937-46. [DOI: 10.1016/j.jpain.2006.05.005]
39. Wild JE, Grond S, Kuperwasser B, Gilbert J, McCann B, Lange B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Practice 2010;10(5):416-27. [DOI: 10.1111/j.1533-2500.2010.00397.x]
40. Wörz R, Frank M, Achenbach U. Controlled-release oxycodone - a therapeutic option for severe neuropathic pain. MMW Fortschritte der Medizin 2003;145(39):45. [PUBMED: 15490770]
41. Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Moore BJ. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain 2010;11(5):462-71. [DOI: 10.1016/j.jpain.2009.09.003.]
42. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 2010;17(9):1113-e88. [DOI: 10.1111/j.1468-1331.2010.02999.x]
43. Ballantyne JC, Kalso E, Stannard C. WHO analgesic ladder: a good concept gone astray. BMJ 2016;352:i20. [DOI: 10.1136/bmj.i20]
44. Baron R, Wasner G, Binder A. Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology 2012;11(1):19-21. [DOI: 10.1016/S1474-4422(11)70281-2]
45. Bostick GP, Toth C, Carr EC, Stitt LW, Morley-Forster P, Clark AJ, et al. Physical functioning and opioid use in patients with neuropathic pain. Pan Medicine 2015;6(7):1361-8. [DOI: 10.1111/pme.12702]
46. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-7. [DOI: 10.1016/j.pain.2007.08.013]
47. Brennan MJ. The effect of opioid therapy on endocrine function. American Journal of Medicine 2013;126(3 Suppl 1):S12-8. [DOI: 10.1016/j.amjmed.2012.12.001]
48. Butler SF, Cassidy TA, Chilcoat H, Black RA, Landau C, Budman SH, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. Journal of Pain 2013;14(4):351-8. [DOI: 10.1016/j.jpain.2012.08.008]
49. Calvo M, Dawes JM, Bennett DL. The role of the immune system in the generation of neuropathic pain. Lancet Neurology 2012;11(7):629-42. [DOI: 10.1016/S1474-4422(12)70134-5]
50. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:f2304. [DOI: 10.1136/bmj.f2304]
51. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 2014;155(11):2263-73. [DOI: 10.1016/j.pain.2014.08.014]
52. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111]
53. Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3]
54. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010958.pub2]
55. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Canadian Medical Association Journal 2009;181(12):891-6. [DOI: 10.1503/cmaj.090784]
56. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132(3):237-51. [DOI: 10.1016/j.pain.2007.08.033]
57. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
58. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [DOI: 10.1093/ije/31.1.140]
59. Finnerup NB, Scholz J, Attal N, Baron R, Haanpää M, Hansson P, et al. Neuropathic pain needs systematic classification. European Journal of Pain 2013;17(7):953-6. [DOI: 10.1002/j.1532-2149.2012.00282.x]
60. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology 2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]
61. Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD002763.pub2]
62. McMaster University (developed by Evidence Prime, Inc.). GRADEpro Guideline Development Tool [Software]. Available from www.gradepro.org (accessed 3 March 2016). McMaster University (developed by Evidence Prime, Inc.), 2016.
63. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132-6. [DOI: 10.1111/j.1399-6576.2007.01486.x]
64. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151-7. [DOI: 10.1016/j.jclinepi.2012.01.006]
65. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72. [DOI: 10.1016/j.jclinepi.2012.01.012]
66. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26]
67. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice 2013;14:28. [DOI: 10.1186/1471-2296-14-28]
68. Helfert SM, Reimer M, Höper J, Baron R. Individualized pharmacological treatment of neuropathic pain. Clinical Pharmacology and Therapeutics 2015;97(2):135-42. [DOI: 10.1002/cpt.19]
69. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [update March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
70. Higgins JPT, Altman DG, Sterne JAC. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
71. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194-201. [DOI: 10.1016/j.pain.2009.09.017]
72. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [DOI: 10.1016/0197-2456(95)00134-4]
73. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204-5. [DOI: 10.1016/j.pain.2011.06.017]
74. Kalso E. How different is oxycodone from morphine?. Pain 2007;132(3):227-8. [DOI: 10.1016/j.pain.2007.09.027]
75. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339]
76. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991;10:276-81. [PUBMED: 1798430]
77. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine 1996;156(6):661-6. [DOI: 10.1001/archinte.1996.00440060089011]
78. Kim M, Chow W, Benson C. Rationale and design of the Oxycodone Users Registry: a prospective, multicenter registry of patients with nonmalignant pain. Journal of Opioid Management 2013;9(3):189-204. [DOI: 10.5055/jom.2013.0160]
79. Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1-3):122-7. [DOI: 10.1016/j.pain.2009.08.023]
80. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33. [DOI: 10.7326/0003-4819-107-2-224]
81. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3]
82. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006146.pub2]
83. McQuay H, Moore R. An Evidence-Based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-263048-2]
84. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
85. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
86. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]
87. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]
88. Moore RA, Straube S, Derry S, McQuay HJ. Chronic low back pain analgesic studies - a methodological minefield. Pain 2010;149(3):431-4. [DOI: 10.1016/j.pain.2010.02.032]
89. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]
90. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]
91. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7. [DOI: 10.1016/j.pain.2010.07.013]
92. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: 10.1016/j.pain.2010.11.030]
93. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569]
94. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
95. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]
96. Moore RA, Straube S, Aldington D. Pain measures and cut-offs-'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
97. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690]
98. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94. [DOI: 10.1111/papr.12050]
99. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94. [DOI: 10.1111/papr.12050]
100. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3]
101. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain 2014;18(1):67-75. [DOI: 10.1002/j.1532-2149.2013.00341.x]
102. Moore RA, Wiffen PJ, Eccleston C, Derry S, Baron R, Bell RF, et al. Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain 2015;156(8):1382-95. [DOI: 10.1097/j.pain.0000000000000088]
103. National Institute for Health and Clinical Excellence. Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings, 2013. www.nice.org.uk/guidance/CG173 (accessed 26 January 2016).
104. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515]
105. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x]
106. Olkkola KT, Hagelberg NM. Oxycodone: new 'old' drug. Current Opinions in Anaesthesiology 2009;22(4):459-62. [DOI: 10.1097/ACO.0b013e32832bc818]
107. Olkkola KT, Kontinen VK, Saari TI, Kalso EA. Does the pharmacology of oxycodone justify its increasing use as an analgesic?. Trends in Pharmacological Sciences 2013;34(4):206-14. [DOI: 10.1016/j.tips.2013.02.001]
108. Cochrane Pain, Palliative and Supportive Care Group (PaPaS) author and referee guidance. papas.cochrane.org/papas-documents (accessed 26 January 2016).
109. Poyhia R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. Journal of Pain & Symptom Management 1993;8(2):63-7. [PUBMED: 8492004]
110. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain 1994;56:127-38. [DOI: 10.1016/0304-3959(94)90086-8]
111. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
112. Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS. Oxycodone for cancer-related pain. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5]
113. Sommer C, Welsch P, Klose P, Schaefert R, Petzke F, Häuser W. Opioids in chronic neuropathic pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015;29(1):35-46. [DOI: 10.1007/s00482-014-1455-x]
114. Stannard C. Opioids in the UK: what's the problem?. BMJ 2013;347:f5108. [DOI: 10.1136/bmj.f5108]
115. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266-75. [DOI: 10.1111/j.1365-2125.2008.03200.x]
116. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29]
117. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin: results from a general population survey. Journal of Pain 2006;7(4):281-9. [DOI: 10.1016/j.jpain.2005.11.008]
118. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-5. [DOI: 10.%E2%80%8B1212/%E2%80%8B01.%E2%80%8Bwnl.%E2%80%8B0000282763.%E2%80%8B29778.%E2%80%8B59]
119. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155(4):654-62. [DOI: 10.1016/j.pain.2013.11.013]
120. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73(4):638-52. [DOI: 10.1016/j.neuron.2012.02.008]
121. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2]
122. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2]
123. Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD010692.pub2]